Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Stomach Neoplasms 56Carcinoma, Hepatocellular 43Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Lung Neoplasms 9Esophageal Neoplasms 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Glioma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

Docetaxel 8Filgrastim 5Cisplatin 5Radiotherapy 4Etoposide 3Erlotinib Hydrochloride 3Cetuximab 3Capecitabine 3Bevacizumab 3sargramostim 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Carboplatin 2Acupuncture Therapy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tanespimycin 1pentetreotide 1oncogene protein E7, Human papillomavirus type 16 1olaparib 1oblimersen 1lutetium Lu 177 dotatate 1etoposide phosphate 1entinostat 1enasidenib 1cevimeline 1apatinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esthesioneuroblastoma, Olfactory × apatinib × Clear all
NCT06308575 2025-01-10

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNS

Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡